6d
MedPage Today on MSNRapid, Substantial Psoriasis Improvement With Oral IL-23 InhibitorTwo-thirds of patients with moderate or severe plaque psoriasis had complete or nearly complete clearance at 4 months with an ...
5d
MedPage Today on MSNTYK2 Inhibitor Scores Two Wins Outside Plaque PsoriasisThe TYK2 inhibitor deucravacitinib (Sotyktu) showed clinical potential in two diseases other than psoriasis, according to ...
Karishmma Chawla, a Functional Medicine & Lifestyle Educator, explains, “Food is the most intimate part of our body. It ...
Johnson & Johnson’s once-daily oral peptide has bested Bristol Myers Squibb’s reigning oral psoriasis med Sotyktu in a ...
A study finds that 99% of dietary advice for psoriasis on Instagram is low-quality, often unsubstantiated and posted by ...
Dry skin, itching, and fiery eczema can be caused by allergens, stress, or an overactive immune response.Steroid creams ...
8d
Medpage Today on MSNHumira Copycats for Psoriasis Backed by Real-World OutcomesIn a cohort of more than 11,000 patients from the U.K. and Ireland, a comparable proportion of new adalimumab users achieved ...
Positive results were reported for Johnson & Johnson's psoriasis drug during.a late-breaking research session today at the ...
A diet of fruits and vegetables, whole grains, low-fat dairy foods and lean meats, low in salt and sugar, is associated with ...
Adults and adolescents treated with icotrokinra experienced improvements in their moderate to severe plaque psoriasis, ...
Two posters presented at the 2025 American Academy of Dermatology Annual Meeting highlighted the importance of improving ...
Results from multiple Phase III trials of Icotrokinra in moderate-to-severe plaque psoriasis and a Phase IIb trial in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results